How lenalidomide is changing the treatment of patients with multiple myeloma

Critical Reviews in Oncology/Hematology

Volumn 88, Issue SUPPL.1, 2013, Pages

  Dimopoulos, Meletios A ^a   Terpos, Evangelos ^a   Niesvizky, Ruben ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Dexamethasone; Lenalidomide; Multiple myeloma

Indexed keywords

ACETYLSALICYLIC ACID; ANTHRACYCLINE; ANTICOAGULANT AGENT; BORTEZOMIB; CARFILZOMIB; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ELOTUZUMAB; ERYTHROPOIETIN; IMMUNOMODULATING AGENT; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; PREDNISONE; THALIDOMIDE;

ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLOOD TOXICITY; CANCER GROWTH; CANCER RECURRENCE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG STRUCTURE; DRUG TOLERABILITY; FATIGUE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; IMMUNOMODULATION; INDUCTION CHEMOTHERAPY; INFECTION; LOW DRUG DOSE; MULTIPLE MYELOMA; MUSCLE WEAKNESS; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PNEUMONIA; RECOMMENDED DRUG DOSE; REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

DEXAMETHASONE; LENALIDOMIDE; MULTIPLE MYELOMA;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE MYELOMA; THALIDOMIDE;

EID: 84882726646     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.05.013     Document Type: Review

References (100)

1. ® (lenalidomide). Summary of Product Characteristics [accessed 24 May 2013]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000717/WC500056018.pdf.
2. Muller G.W., Chen R., Huang S.Y., et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorganic and Medicinal Chemistry Letters 1999, 9:1625-1630.
3. McCarthy P.L., Owzar K., Hofmeister C.C., et al. Lenalidomide after stem-cell transplantation for multiple myeloma. New England Journal of Medicine 2012, 366:1770-1781.
4. Attal M., Lauwers-Cances V., Marit G., et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. New England Journal of Medicine 2012, 366:1782-1791.
5. Palumbo A., Hajek R., Delforge M., et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. New England Journal of Medicine 2012, 366:1759-1769.
6. List A., Dewald G., Bennett J., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. New England Journal of Medicine 2006, 355:1456-1465.
7. Chanan-Khan A., Miller K.C., Musial L., et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. Journal of Clinical Oncology 2006, 24:5343-5349.
8. Wiernik P., Lossos I.S., Tuscano J.M., et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkins lymphoma. Journal of Clinical Oncology 2008, 26:4952-4955.
9. Vallet S., Palumbo A., Raje N., Boccadoro M., Anderson K.C. Thalidomide and lenalidomide: mechanism-based potential drug combinations. Leukemia and Lymphoma 2008, 49:1238-1245.
10. Corral L.G., Haslett P.A.J., Muller G.W., et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. Journal of Immunology 1999, 163:380-386.
11. + progenitor cells. Cancer Research 2007, 67:746-755.
12. WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Research 2009, 69:7347-7356.
13. Lopez-Girona A., Mendy D., Brady H., Gaidarova S. Lenalidomide inhibits the multiple myeloma cell survival factor IRF4/MUM1. Clinical Lymphoma and Myeloma 2009, 9(Suppl. 1). [abstract 309].
14. Mitsiades N., Mitsiades C.S., Poulaki V., et al. Apoptotic signalling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002, 99:4525-4530.
15. Gandhi A.K., Kang J., Capone L., et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Current Cancer Drug Targets 2010, 10:155-167.
16. Hideshima T., Chauhan D., Shima Y., et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000, 96:2943-2950.
17. Davies F.E., Raje N., Hideshima T., et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001, 98:210-216.
18. + T cells. Clinical and Experimental Immunology 2002, 130:75-84.
19. Chang D.H., Liu N., Klimek V., et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 2006, 108:618-621.
20. Galustian C., Meyer B., Labarthe M.C., et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunology, Immunotherapy 2009, 58:1033-1045.
21. Raja K.M., Plasil M., Kovarova L., Stossova J., Hajek R. Induction by lenalidomide and dexamethasone combination increases CD4 and CD8 regulatory cells of newly diagnosed multiple myeloma patients. Haematologica 2011, 96(Suppl. 2). [abstract 0848].
22. Clave E., Douay C., Bompoint C., et al. Lenalidomide treatment post-autologous transplantation for multiple myeloma decreases terminally differentiated CD4 and CD8 T cells and increases number of TREG. Haematologica 2011, 96(Suppl 2). [abstract 0850].
23. Noonan K., Rudraraju L., Ferguson A., et al. Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses. Clinical Cancer Research 2012, 18:1426-1434.
24. Hideshima T., Anderson K.C. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nature Reviews Cancer 2002, 2:927-937.
25. Li S., Pal R., Monaghan S.A., et al. IMiD immunomodulatory compounds block C/EBPβ translation through eIF4E down-regulation resulting in inhibition of MM. Blood 2011, 117:5157-5165.
26. Dredge K., Horsfall R., Robinson S.P., et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvascular Research 2005, 69:56-63.
27. DeLuisi A., Ferrucci A., Coluccia A.M.L., et al. Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma. Clinical Cancer Research 2011, 17:1935-1946.
28. Jakubikova J., Adamia S., Kost-Alimova M., et al. Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood 2011, 117:4409-4419.
29. Ito T., Ando H., Suzuki T., et al. Identification of a primary target of thalidomide teratogenicity. Science 2010, 327:1345-1350.
30. Chang X.B., Stewart A.K. What is the functional role of the thalidomide binding protein cereblon?. International Journal of Biochemistry and Molecular Biology 2011, 2:287-294.
31. Zhu Y.X., Braggio E., Shi C.X., et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011, 118:4771-4779.
32. Lopez-Girona A., Mendy D., Ito T., et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012, 26:2326-2335.
33. Heintel D., Bolomsky A., Schreder M., et al. High expression of the thalidomide-binding protein cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Blood 2011, 118. [abstract 2879].
34. Palumbo A., Rocci A., Ludwig H., Dimopoulos M.A. Lenalidomide for multiple myeloma: Dr Palumbo and colleagues reply. New England Journal of Medicine 2012, 367:573-575.
35. Dimopoulos M., Spencer A., Attal M., et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. New England Journal of Medicine 2007, 357:2123-2132.
36. Weber D., Chen C., Niesvizky R., et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. New England Journal of Medicine 2007, 357:2133-2142.
37. Chen N., Lau H., Kong L., et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on dialysis. Journal of Clinical Pharmacology 2007, 47:1466-1475.
38. Richardson P.G., Schlossman R.L., Weller E., et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002, 100:3063-3067.
39. Richardson P., Jagannath S., Hussein M., et al. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 2009, 114:772-778.
40. Dimopoulos M.A., Chen C., Spencer A., et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009, 23:2147-2152.
41. Alegre A., Aguado B., Giraldo P., et al. Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients. International Journal of Hematology 2011, 93:351-360.
42. Spina F., Montefusco V., Cripa C., et al. Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant. Leukemia and Lymphoma 2011, 52:1262-1270.
43. Moscetti A., Saltarelli F., Bianchi M.O., et al. Lenalidomide and dexamethasone in relapsed and refractory multiple myeloma: a monocentric experience. IMW 2011, [abstract 455].
44. Stadtmauer E.A., Weber D.M., Niesvizky R., et al. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. European Journal of Haematology 2009, 82:426-432.
45. Harousseau J.L., Dimopoulos M.A., Wang M., et al. Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica 2010, 95:1738-1744.
46. San Miguel J.F., Dimopoulos M.A., Stadtmauer E.A., et al. Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Clinical Lymphoma Myeloma and Leukemia 2011, 11:38-43.
47. Dimopoulos M.A., Palumbo A., Attal M., et al. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia 2011, 25:749-760.
48. Wang M., Dimopoulos M.A., Chen C., et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 2008, 112:4445-4451.
49. Guglielmelli T., Bringhen S., Rrodhe S., et al. Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients. European Journal of Cancer 2011, 47:814-818.
50. Mateos M.V., Richardson P.G., Schlag R., et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA Trial. Journal of Clinical Oncology 2010, 28:2259-2266.
51. Chanan-Khan A.A., Yu Z., Weber D., et al. Lenalidomide (L) in combination with dexamethasone (D) significantly improves time to progression (TTP) in non-stem cell transplant patients (pts) with relapsed or refractory (rel/ref) multiple myeloma (MM): analysis from MM-009 and MM-010 randomized phase III clinical trials. Blood 2006, 108. [abstract 3554].
52. Stewart A.K., Bergsagel P.L., Greipp P.R., et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 2007, 21:529-534.
53. Reece D., Song K.W., Fu T., et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion of 17p13. Blood 2009, 114:522-525.
54. Dimopoulos M.A., Alegre A., Stadtmauer E.A., et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer 2010, 116:3807-3814.
55. Dimopoulos M.A., Christoulas D., Roussou M., et al. Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. European Journal of Haematology 2010, 85:1-5.
56. Knudsen L.M., Hjorth M., Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. European Journal of Haematology 2000, 65:175-181.
57. Klein U., Neben K., Hielscher T., Heiss C., Ho A.D., Goldschmidt H. Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment. Annals of Hematology 2011, 90:429-439.
58. Cavo M., Rajkumar S.V., Palumbo A., et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 2011, 117:6063-6073.
59. Delforge M., Bladé J., Dimopoulos M.A., et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncology 2010, 11:1086-1095.
60. Bringhen S., Falco P., Rossi D., et al. A multicenter open-label study of lenalidomide and prednisone (RP) followed by lenalidomide, melphalan and prednisone (MPR) in newly-diagnosed elderly multiple myeloma patients. Haematologica 2011, 96(Suppl. 2). [abstract 0294].
61. Zonder J.A., Crowley J., Hussein M.A., et al. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood 2010, 116:5838-5841.
62. Rajkumar S.V., Jacobus S., Callander N.S., et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncology 2010, 11:29-37.
63. Gay F., Hayman S., Buadi F., et al. Safety and efficacy of lenalidomide plus dexamethasone in elderly newly diagnosed multiple myeloma patients 70 years of age and older. Haematologica 2010, 95(Suppl. 2). [abstract 0379].
64. Gay F., Hayman S.R., Lacy M.Q., et al. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma. Blood 2010, 115:1343-1350.
65. Boccadoro M., Cavallo F., Nagler A., et al. Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) in newly-diagnosed multiple myeloma patients: a phase III trial. Journal of Clinical Oncology 2011, 29(Suppl.). [abstract 8020].
66. Niesvisky R., Jayabalan D.S., Christos P.J., et al. BiRD (biaxcin [clarithromycin]/revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete and overall response rates in treatment-naïve symptomatic multiple myeloma. Blood 2008, 111:1101-1109.
67. Jakubowiak A.J., Griffith K.A., Reece D.E., et al. Lenalidomide, bortezomib, peglycated liposomal doxorubicin and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. Blood 2011, 118:535-543.
68. Kumar S.K., Lacy M.A., Hayman S.R., et al. Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. American Journal of Hematology 2011, 86:640-645.
69. Kumar S., Dispenzieri A., Lacy M.Q., et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007, 21:3025-3042.
70. ClinicalTrials.gov. Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma (FIRST). [accessed 11.1.11]. http://www.clinicaltrials.gov/ct2/show/NCT00689936.
71. Lonial S., Baz R., Swern A.S., Weber D., Dimopoulos M.A. Neutropenia is a predictable and early event in affected patients with relapsed/refractory multiple myeloma treated with lenalidomide in combination with dexamethasone. Blood 2009, 114. [abstract 2879].
72. Stadtmauer E.A., Lonial S., Vesole D.H., et al. A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings. Clinical Advances in Hematology and Oncology 2007, 5(Suppl. 15):7-19.
73. Carrier M., Le Gal G., Tay J., Wu C., Lee A.Y. Rates of venous thromboembolism in multiple myeloma patients undergoing immunmodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis 2011, 9:653-663.
74. Bohlius J., Wilson J., Seidenfeld J., et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. Journal of the National Cancer Institute 2006, 98:708-714.
75. Palumbo A., Rajkumar S.V., Dimopoulos M.A., et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008, 22:414-423.
76. Delforge M., Facon T., Bravo M.L., Dimopoulos M.A. Lenalidomide plus dexamethasone has similar tolerability and efficacy in treatment of relapsed/refractory multiple myeloma patients with or without history of neuropathy. Blood 2009, 114. [abstract 3873].
77. Masini L., Hernandez M., Hajek R., et al. An update on the overall safety and incidence of SPM in lenalidomide, thalidomide, and bortezomib-treated patients within the European Post-Approval Safety Study (EU PASS) of relapsed/refractory MM. Haematologica 2012, 97(Suppl. 1):340. [abstract 0831].
78. Altekruse S.F., Kosary C.L., Krapcho M., et al. SEER Cancer Statistics Review, 1975-2007 2010, National Cancer Institute, Bethesda, MD, http://seer.cancer.gov/csr/1975_2007, based on November 2009 SEER data submission, posted to the SEER website.
79. Dong C., Hemminki K. Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958-1966: a search for common mechanisms. British Journal of Cancer 2001, 85:997-1005.
80. Dores G.M., Cote T.R., Travis L. New malignancies following Hodgkin lymphoma, non-Hodgkin lymphoma, and myeloma. New malignancies among cancer survivors: SEER Cancer Registries, 1973-2000. NIH Publ. No. 05-5302 2006, National Cancer Institute, Bethesda, MD, [accessed 11.1.11]. http://seer.cancer.gov/publications/mpmono/MPMonograph_complete.pdf, R.E. Curtis, D.M. Freedman, E. Ron, L.A.G. Ries, D.G. Hacker, B.K. Edwards (Eds.).
81. Hasskarl J., Ihorst G., De Pasquale D., et al. Association of multiple myeloma with different neoplasms: systematic analysis in consecutive patients with myeloma. Leukemia and Lymphoma 2011, 52:247-259.
82. Palumbo A.P., Delforge M., Catalano J., et al. Incidence of second primary malignancy (SPM) in melphalan-prednisone-lenalidomide combination followed by lenalidomide maintenance (MPR-R) in newly diagnosed multiple myeloma patients (pts) age 65 or older. Journal of Clinical Oncology 2011, 29(Suppl.). [abstract 8007].
83. Attal M., Olivier P., Cances Lauwers V., et al. Maintenance treatment with lenalidomide after transplantation for myeloma: analysis of secondary malignancies with the IFM 2005-02 trial. Haematologica 2011, 96(Suppl. 1):S23.
84. Palumbo A., Bringhen S., Zweegman S., et al. Secondary malignancies in elderly myeloma patients. Haematologica 2011, 96(Suppl. 1):S24.
85. Rossi A.C., Mark T.M., Jayabalan D., et al. Incidence of second primary malignancies (SPM) after 6-years follow-up of continuous lenalidomide in first-line treatment of multiple myeloma (MM). Journal of Clinical Oncology 2011, 29(Suppl.). [abstract 8008].
86. Dimopoulos M.A., Richardson P.G., Brandenburg N.A., et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood 2012, 119:2764-2767.
87. Landgren O., Thomas A., Mailankody S. Myeloma and second primary cancers. New England Journal of Medicine 2011, 365:2241-2242.
88. Cives M., Simone V., Brunetti O., Longo V., Silvestris F. Novel lenalidomide-based combinations for treatment of multiple myeloma. Critical Reviews in Oncology/Hematology 2013, 85:9-20.
89. Morgan G.J., Schey S.A., Wu P., et al. (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. British Journal of Haematology 2007, 137:268-269.
90. Richardson P.G., Weller E., Lonial S., et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010, 116:679-686.
91. Richardson P.G., Weller E., Jagannath S., et al. Multicenter, phase 1, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma (MM). Journal of Clinical Oncology 2009, 27:5713-5719.
92. Anderson K.C., Jagannath S., Jakubowiak S., et al. Lenalidomide, bortezomib and dexamethasone in relapsed/refractory multiple myeloma (MM): encouraging outcomes and tolerability in a phase II study. Journal of Clinical Oncology 2009, 27(Suppl. 15). [abstract 8536].
93. Dimopoulos M.A., Kastritis E., Christoulas D., et al. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia 2010, 24:1769-1778.
94. Niesvisky R., Bensinger W., Martin T., et al. An update on the phase 1b/2 dose-escalation study of carfilzomib with lenalidomide and low-dose dexamethasone (CRd) in patients with relapsed or refractory multiple myeloma. Haematologica 2011, 96(Suppl. 2). [abstract 0295].
95. Jakobowiak A.J., Dytfeld D., Griffith K.A., et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 2012, 120:1801-1809.
96. Moreau P., Palumbo A.P., Stewart A.K., et al. A randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM). Journal of Clinical Oncology 2011, 29(Suppl.). [abstract TPS225].
97. Korde N., Zingone A., Kwok M., et al. Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone (CRd) in newly diagnosed multiple myeloma (MM) patients. Blood 2012, 120. [abstract 732].
98. Moreau P., Richardson P., Lonial S., et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in patients with relapsed multiple myeloma: a randomized phase 2 study. Haematologica 2011, 96(Suppl.). [abstract 1007].
99. ClinicalTrials.gov. Lenalidomide and dexamethasone with or without bortezomib in treating patients with previously untreated multiple myeloma. [accessed 11.1.11]. http://www.clinicaltrials.gov/ct2/show/NCT00644228.
100. ClinicalTrials.gov. Randomized trial of lenalidomide, bortezomib, dexamethasone vs high-dose treatment with SCT in MM patients up to age 65 (DFCI 10-106). [accessed 11.1.11]. http://www.clinicaltrials.gov/ct2/show/NCT01208662.